MDS Pharma Services Opens Largest Phase I Clinic on U.S. West Coast
25 Gennaio 2008 - 2:00PM
PR Newswire (US)
New 300-bed facility in Tempe, Arizona, raises MDS capacity in the
Phoenix-area to 420 total beds KING OF PRUSSIA, PA, Jan. 25
/PRNewswire-FirstCall/ -- MDS Pharma Services
(http://www.mdsps.com/), a leading provider of innovative drug
discovery and development solutions, has expanded its presence in
the Phoenix area with a new 300-bed Phase I facility in nearby
Tempe, Arizona. The $25 million facility more than doubles the
previous MDS Phase I capacity in Phoenix to 420 total beds to meet
the growing needs of its pharmaceutical and biotech clients. Part
of an extensive global network of European and North American Phase
I locations, the new facility brings the MDS Pharma Services global
total to more than 1,100 beds. In addition to a specialized area
for conducting cardiac safety trials, the new facility also offers
specialized ophthalmic capabilities, as well as a range of other
specialty Phase I services. Purpose-built from the ground up to be
a Phase I clinic, the new facility has a state-of-the art clinical
lab and secure pharmacy, comfortable accommodations for study
participants and well-appointed areas for visiting clients. "Client
needs were top-of-mind when we decided to expand in Phoenix - the
fastest growing urban area in the United States," said MDS Pharma
Services President David Spaight. "The Phoenix location offers
several advantages to our clients, including travel convenience,
access to a large and varied study participant pool, and an
experienced and educated workforce to staff the new clinic and
laboratory." The workforce for the new facility is drawn from the
same experienced team that operated the earlier MDS Pharma Services
Phoenix clinic, where they achieved a better than 97% on-time study
start-up record. MDS Pharma Services has had a Phase I operation in
Phoenix for more than two decades, conducting more than 600
clinical trials involving some 13,000 participants. Its current
Phoenix workforce of more than 150 could triple when the new
facility is running at full capacity. About MDS Pharma Services MDS
Pharma Services is committed to delivering quality results on time.
We offer a full spectrum of resources to meet the drug discovery
and development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around
the world, we apply advanced scientific and technological expertise
throughout the drug discovery and development process - from lead
optimization, pre-IND research, early clinical research
(bioequivalence, phases I-IIa) and bioanalysis through to global
clinical development (phases IIb-IV), central lab and centralized
cardiac services. For more information, visit our website at
http://www.mdsps.com/. MDS Pharma Services is a business unit of
MDS Inc. (TSX: MDS; NYSE: MDZ), a global life sciences company that
provides market-leading products and services that our customers
need for the development of drugs and diagnosis and treatment of
disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than
5,500 highly skilled people in 28 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. DATASOURCE: MDS Pharma Services CONTACT: For Investors: Sharon
Mathers, (416) 675-6777 ext. 34721, ; For Media: Charlene McGrady,
(610) 239-7900 ext. 231,
Copyright